<DOC>
	<DOCNO>NCT00833729</DOCNO>
	<brief_summary>To describe response etanercept adalimumab fail produce satisfactory response moderate severe plaque psoriasis . A total 10 patient moderate severe psoriasis currently use adalimumab least 12 week PGA mild worse transition etanercept 50 mg twice weekly ( BIW ) 12 wks follow dose reduction 50mg weekly ( OW ) additional 12 week .</brief_summary>
	<brief_title>The Safety &amp; Efficacy Etanercept Psoriasis Patients Who Have Not Responded Adalimumab</brief_title>
	<detailed_description>A total 10 patient moderate severe psoriasis currently use adalimumab least 12 week PGA mild worse transition etanercept 50 mg twice weekly ( BIW ) 12 wks follow dose reduction 50mg weekly ( OW ) additional 12 week .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subject ≥ 18 year age . Subject diagnosis moderate severe chronic plaque psoriasis least 6 month Subject suboptimal response continuous treatment adalimumab administer least 3 consecutive month prior screen , treatment interruption exceed 14 day , dose 40 mg every week ( eow ) load 80mg sc . The last dose adalimumab must great 11 day less 17 day first dose etanercept . PGA mild bad If female , subject either childbearing potential , defined postmenopausal least 1 year surgically sterile childbearing potential practicing approve method birth control throughout study . The result urine pregnancy test perform screen visit must negative . Subject judge generally good health determine Investigator base upon result medical history , laboratory profile , physical examination perform screen . Subject must able selfadminister qualify designee reliably administer SC injection . Subject must able willing give write informed consent comply requirement study protocol . Subject negative PPD test within 6 month screen . Able start etanercept per approve Enbrel® product monograph Previous treatment etanercept Subject receive require : UVB phototherapy , ( narrowband UVB ) , excessive sun exposure use tan booth within 14 day prior Baseline visit . PUVA phototherapy within 14 day prior Baseline visit . Systemic nonbiologic therapy psoriasis within 30 day prior Baseline visit . Biologic therapy ( exclude adalimumab ) psoriasis within 30 day prior Baseline visit . High potentcy topical steroid study period Received investigational agent within 30 day 5 half life prior Baseline ( whichever longer ) , within duration know pharmacological activity . Subject active skin disease skin infection ( bacterial , fungal , viral parasitic ) may interfere evaluation psoriasis . Infection ( ) require treatment intravenous ( IV ) antibiotic , IV antiviral , IV antifungal within 30 day prior Baseline oral antibiotic , oral antiviral , oral antifungal within 14 day prior Baseline . History moderate severe congestive heart failure ( NYHA class III IV ) , recent cerebrovascular accident condition , opinion investigator , would put subject risk participation protocol . History CNS demyelinate disease neurologic symptom suggestive CNS demyelinate disease . History listeriosis , histoplasmosis , chronic active Hepatitis B infection , human immunodeficiency virus ( HIV ) infection , immunodeficiency syndrome , chronic recur infection active TB . Known hypersensitivity excipients etanercept state label . Erythrodermic psoriasis generalize localized pustular psoriasis , medication−induced medicationexacerbated psoriasis new onset guttate psoriasis . Female subject pregnant breastfeed consider become pregnant study . Evidence dysplasia history malignancy ( include lymphoma leukemia ) successfully treat nonmetastatic cutaneous squamous cell , basal cell carcinoma localize carcinoma situ cervix . History clinically significant drug alcohol abuse last 12 month . Subject consider Investigator , reason , unsuitable candidate study able comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>etanercept</keyword>
	<keyword>adalimumab</keyword>
	<keyword>moderate severe plaque psoriasis</keyword>
</DOC>